RWJ 50271
RWJ 50271 性质
| 密度 | 1.44±0.1 g/cm3(Predicted) |
|---|---|
| 储存条件 | Store at RT |
| 溶解度 | <41.04mg/ml，溶于 DMSO |
| 酸度系数(pKa) | 14.28±0.46(Predicted) |
| 形态 | 固体 |
| 颜色 | 白色至米白色 |
RWJ 50271 用途与合成方法
IC50: 5.0 μM (LFA-1/ICAM-1, HL60 cells)
RWJ 50271 inhibits adhesion of peripheral blood lymphocytes to plastic immobilized SICAM-1.
RWJ 50271 inhibits both human and murine NK activity (IC
50
=5.0 μM) in an LFA-1/ICAM-1-dependent natural killer [NK] cytotoxicity assay.
RWJ 50271 does not inhibit Mac-1/ICAM-1, E-selectidsialyl Lewis X or VLA-4/VCAM-1-mediated cell adhesion up to 20 μM concentrations.
RWJ 50271 does not alter the LFA-1 expression levels on HL60 cells.
RWJ 50271 inhibits adhesion of peripheral blood lymphocytes to plastic immobilized SICAM-1.
RWJ 50271 does not exhibit any toxic activity up to 100 μM concentrations.
RWJ 50271 (50 mg/kg; p.o.) is effective in animal model of inflammation.
| Animal Model: | Mice, the delayed-type hypersensitivity [DTH] reaction model |
| Dosage: | 50 mg/kg |
| Administration: | Oral administration |
| Result: | Significantly reduced foot pad swelling (>50%) 48 h after the challenge. |
RWJ 50271 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-04-30 | HY-110086 | 1 mg | 900 | ||
| 2024-04-30 | HY-110086 | RWJ 50271 | 162112-37-0 | 5mg | 1800 |
